1. Insulin lowers blood glucose primarily by increasing glucose uptake into skeletal muscle and adipose tissue. Which cellular event is the principal effector of this insulin-stimulated glucose uptake?
A) Increased transcription of the gene encoding the insulin receptor, raising the number of receptors available at the cell surface
B) Translocation of intracellular GLUT4 (glucose transporter type 4)-containing storage vesicles to the plasma membrane, increasing the cell's glucose uptake capacity
C) Direct phosphorylation of free cytoplasmic glucose by the insulin receptor, trapping glucose inside the cell
D) Opening of ligand-gated glucose channels in the plasma membrane in response to insulin binding at the extracellular surface
E) Activation of the MAPK (mitogen-activated protein kinase) arm of insulin signaling, which drives the metabolic glucose-lowering response
ANSWER: B
Rationale:
Insulin-stimulated glucose uptake in skeletal muscle and adipose tissue is mediated by the regulated translocation of GLUT4 (glucose transporter type 4) storage vesicles to the plasma membrane. Activated Akt phosphorylates AS160, inactivating its GAP (GTPase-activating protein) activity and allowing Rab to adopt its active GTP-bound state, which triggers vesicle translocation; skeletal muscle alone accounts for roughly 75 to 80 percent of postprandial glucose disposal in the insulin-stimulated state.
Option A: Option A is incorrect because the acute glucose-lowering effect of insulin operates on a timescale of minutes and does not depend on new receptor transcription; receptor number is not the rate-limiting step in postprandial glucose disposal.
Option C: Option C is incorrect because glucose phosphorylation is carried out by hexokinase/glucokinase after glucose has entered the cell, not by the insulin receptor, and it is transport across the membrane (not trapping of pre-existing cytoplasmic glucose) that insulin acutely controls.
Option D: Option D is incorrect because GLUT4 is a facilitative transporter that moves glucose down its concentration gradient, not a ligand-gated ion channel, and there are no insulin-gated glucose channels.
Option E: Option E is incorrect because the MAPK arm mediates insulin's mitogenic and growth effects and does not contribute to glucose lowering, which is driven by the PI3K-Akt arm.
2. A trainee asks how the insulin receptor transmits its signal across the plasma membrane after insulin binds. Which description correctly characterizes the insulin receptor and its proximal signaling mechanism?
A) It is a G protein-coupled receptor (GPCR) that activates adenylyl cyclase, raising intracellular cAMP (cyclic adenosine monophosphate) to drive glucose uptake
B) It is a ligand-gated ion channel that depolarizes the cell upon insulin binding, opening voltage-gated calcium channels
C) It is a steroid-type nuclear receptor that, after insulin enters the cell, binds DNA directly to alter transcription of glucose-handling genes
D) It is a receptor tyrosine kinase that autophosphorylates on insulin binding and then phosphorylates IRS-1 (insulin receptor substrate 1), recruiting PI3K and activating Akt
E) It is a single-pass receptor that signals exclusively through the JAK-STAT pathway, with no role for tyrosine autophosphorylation
ANSWER: D
Rationale:
The insulin receptor is a receptor tyrosine kinase. Insulin binding triggers receptor autophosphorylation on tyrosine residues, creating docking sites for IRS-1 (insulin receptor substrate 1); tyrosine-phosphorylated IRS-1 recruits PI3K (phosphoinositide 3-kinase), which generates PIP3 and activates Akt, the node from which the principal metabolic effects (GLUT4 translocation, glycogen synthesis, suppression of gluconeogenesis and lipolysis) radiate.
Option A: Option A is incorrect because the insulin receptor is not a GPCR and does not raise cAMP to lower glucose; in adipocytes Akt actually lowers cAMP by activating PDE3B.
Option B: Option B is incorrect because the insulin receptor is not a ligand-gated ion channel and does not signal by membrane depolarization.
Option C: Option C is incorrect because insulin is a peptide hormone that does not enter the cell to act as a nuclear receptor; its receptor is a cell-surface transmembrane kinase.
Option E: Option E is incorrect because, although insulin signaling has multiple downstream arms, the proximal mechanism is tyrosine autophosphorylation of the receptor itself rather than exclusive JAK-STAT signaling.
3. Endogenously secreted insulin enters the portal vein before reaching the systemic circulation, whereas subcutaneously injected insulin reaches peripheral tissues first. Which statement correctly describes the consequence of hepatic first-pass insulin handling?
A) The liver extracts roughly 50 to 60 percent of secreted insulin on first pass, creating a hepatic-to-peripheral gradient that subcutaneous dosing cannot reproduce, predisposing to peripheral hypoglycemia at doses needed to suppress hepatic glucose output
B) The liver adds insulin to the portal blood, so peripheral insulin concentrations after endogenous secretion are higher than hepatic concentrations
C) Subcutaneous insulin is preferentially delivered to the portal circulation, reproducing the physiological hepatic-to-peripheral gradient
D) Hepatic insulin extraction is negligible, so portal and peripheral insulin concentrations are essentially equal after endogenous secretion
E) First-pass hepatic extraction destroys all secreted insulin, so peripheral tissues receive insulin only from subcutaneous injection
ANSWER: A
Rationale:
Insulin secreted by beta cells enters the portal circulation, and roughly 50 to 60 percent is extracted by the liver during first pass, producing hepatic insulin concentrations two- to fourfold higher than peripheral concentrations. This gradient lets highly insulin-sensitive hepatic glucose output suppression occur without driving peripheral hypoglycemia. Subcutaneous insulin bypasses portal delivery and reaches muscle and fat before the liver, so peripheral concentrations must be raised to achieve adequate hepatic effect, an inherent limitation that predisposes to peripheral hypoglycemia.
Option B: Option B is incorrect because the liver removes insulin from portal blood rather than adding it, making hepatic concentrations higher and peripheral concentrations lower, not the reverse.
Option C: Option C is incorrect because subcutaneous injection delivers insulin to the systemic (peripheral) circulation first and specifically does not reproduce portal delivery.
Option D: Option D is incorrect because first-pass extraction is substantial, not negligible, and is precisely what creates the portal-peripheral gradient.
Option E: Option E is incorrect because only about half of secreted insulin is extracted on first pass; the remainder reaches the peripheral circulation, so endogenous insulin does reach peripheral tissues.
4. A patient presents with hypoglycemia and a high measured insulin level, and the team wants to know whether the insulin is endogenous or surreptitiously injected. Which measurement best distinguishes endogenous insulin secretion from exogenous insulin administration, and why?
A) Measuring total insulin level, because exogenous and endogenous insulin differ in their absolute plasma concentration
B) Measuring proinsulin only, because it is present exclusively after exogenous insulin injection
C) Measuring C-peptide, because it is co-secreted equimolarly with endogenous insulin but is absent from all commercially available insulin preparations
D) Measuring hemoglobin A1c (glycated hemoglobin), because it rises acutely within minutes of exogenous insulin injection
E) Measuring the MAPK (mitogen-activated protein kinase) signaling output, because only endogenous insulin activates this pathway
ANSWER: C
Rationale:
C-peptide is cleaved from proinsulin and secreted in equimolar amounts with endogenous insulin, but it is absent from all commercially available insulin preparations. A high insulin level with suppressed C-peptide therefore indicates an exogenous source (factitious hypoglycemia from surreptitious injection), whereas high insulin with proportionately elevated C-peptide indicates endogenous hypersecretion.
Option A: Option A is incorrect because a total insulin level alone cannot tell endogenous from exogenous insulin, which is exactly why C-peptide is needed as the discriminator.
Option B: Option B is incorrect because proinsulin reflects endogenous beta-cell secretion, not exogenous insulin, so its logic is inverted.
Option D: Option D is incorrect because HbA1c reflects average glycemia over roughly the preceding 8 to 12 weeks and does not change acutely, so it cannot identify an acute exogenous insulin source.
Option E: Option E is incorrect because both endogenous and exogenous insulin act through the same insulin receptor and downstream pathways, so signaling output cannot distinguish the source.
5. A patient in the intensive care unit requires an intravenous insulin infusion for management of acute hyperglycemia. Which insulin preparation is appropriate for intravenous administration?
A) Insulin glargine, because its acidic formulation is fully soluble in the vial
B) NPH (neutral protamine Hagedorn) insulin, because its protamine complex stabilizes it in intravenous solution
C) Insulin degludec, because its ultra-long duration provides stable intravenous control
D) A premixed 70/30 formulation, because the fixed ratio simplifies infusion dosing
E) Regular insulin, because it is the only preparation suitable for intravenous use
ANSWER: E
Rationale:
Regular insulin is the only preparation suitable for intravenous infusion; analogs, NPH, and premixed formulations must not be given intravenously because of altered pharmacokinetics and, for NPH and premixed suspensions, the risk of particulate matter. Standard ICU protocols titrate a regular insulin infusion against current glucose and rate of change, targeting 140 to 180 mg/dL per NICE-SUGAR (Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation) trial evidence.
Option A: Option A is incorrect because, although glargine is soluble in its acidic vial, it precipitates at neutral subcutaneous pH and is formulated for subcutaneous depot action, not intravenous use.
Option B: Option B is incorrect because NPH is a protamine-zinc suspension whose particulate nature makes it unsuitable and unsafe for intravenous administration.
Option C: Option C is incorrect because degludec is engineered for an ultra-long subcutaneous depot and is not used intravenously.
Option D: Option D is incorrect because premixed formulations contain a protamine-complexed suspension component and cannot be given intravenously.
6. Insulin lispro has a much faster onset of action than regular human insulin. Which structural modification accounts for this accelerated subcutaneous absorption?
A) Addition of a C14 (fourteen-carbon) fatty acid chain that promotes reversible albumin binding and prolongs the depot
B) Reversal of the ProB28-LysB29 sequence to LysB28-ProB29, disrupting the beta-sheet contacts that stabilize dimer formation and favoring the rapidly absorbed monomer state
C) Substitution of AsnA21 with glycine plus addition of two B-chain arginine residues, shifting the isoelectric point so the molecule precipitates at neutral pH
D) Complexing the insulin with protamine and zinc to form a suspension that dissolves slowly after injection
E) Attachment of a C18 (eighteen-carbon) fatty acid that allows formation of large multi-hexamer complexes in the subcutaneous depot
ANSWER: B
Rationale:
Insulin lispro reverses the ProB28-LysB29 sequence to LysB28-ProB29, disrupting the beta-sheet contacts between B-chain C-termini that stabilize dimer formation, without altering the receptor-binding surface. Destabilizing self-association shifts the equilibrium toward monomers, which cross the capillary endothelium rapidly, giving onset within 10 to 15 minutes.
Option A: Option A describes insulin detemir, whose C14 acylation drives albumin binding for a prolonged basal effect, the opposite of a rapid-acting profile.
Option C: Option C describes insulin glargine, whose AsnA21-glycine substitution and added B-chain arginines shift the isoelectric point so it precipitates at neutral subcutaneous pH for slow basal release.
Option D: Option D describes NPH (neutral protamine Hagedorn) insulin, an intermediate-acting protamine-zinc suspension, not a rapid-acting analog.
Option E: Option E describes insulin degludec, whose C18 fatty acid produces ultra-long-acting multi-hexamer depots, again the opposite of rapid action.
7. Insulin glargine is formulated as a clear, fully soluble solution in its vial yet behaves as a long-acting basal insulin after injection. Which mechanism explains its prolonged duration of action?
A) Reversible binding to plasma albumin via a C14 (fourteen-carbon) fatty acid chain that buffers absorption fluctuations
B) Slow dissolution of a protamine-zinc suspension formed during manufacturing
C) Formation of large multi-hexamer complexes in the depot via a C18 (eighteen-carbon) fatty acid that slowly dissociate
D) Precipitation into microprecipitates upon injection into the neutral subcutaneous environment, because the acidic (pH 4) formulation becomes insoluble at physiological pH, creating a slowly dissolving depot
E) Substitution at position B28 that destabilizes the hexamer and accelerates monomer absorption
ANSWER: D
Rationale:
Insulin glargine is engineered by substituting AsnA21 with glycine and adding two arginine residues to the B-chain C-terminus, shifting the isoelectric point from about pH 5.4 to 6.7. The product is acidic (pH 4) and fully soluble in the vial, but on injection into the neutral subcutaneous tissue it precipitates into microprecipitates that dissolve slowly, providing a near-peakless 20- to 24-hour basal effect (longer for the U-300 formulation).
Option A: Option A describes insulin detemir, which prolongs action through C14 fatty acid-mediated albumin binding rather than pH-dependent precipitation.
Option B: Option B describes NPH (neutral protamine Hagedorn) insulin, an intermediate-acting protamine-zinc suspension.
Option C: Option C describes insulin degludec, whose C18 fatty acid forms multi-hexamer depots.
Option E: Option E describes a rapid-acting analog modification that accelerates absorption, the opposite of glargine's basal behavior.
8. Insulin degludec has the longest duration of action among basal insulins, exceeding 42 hours and permitting flexible once-daily timing. Which structural mechanism produces this ultra-long action?
A) A C18 (eighteen-carbon) fatty acid attached to LysB29 allows degludec to form large multi-hexamer complexes in the subcutaneous depot that slowly dissociate into monomers
B) Microprecipitation at neutral subcutaneous pH from an acidic, fully soluble vial formulation
C) Reversal of the ProB28-LysB29 sequence to favor the rapidly absorbed monomer state
D) Complexing with protamine and zinc to form an intermediate-acting suspension
E) Substitution of AsnB3 with lysine and LysB29 with glutamic acid to destabilize self-association
ANSWER: A
Rationale:
Insulin degludec carries a C18 (eighteen-carbon) fatty acid attached to LysB29 that drives formation of large multi-hexamer complexes in the subcutaneous depot; these slowly dissociate into monomers, producing a duration exceeding 42 hours, a near-peakless profile, low intra-patient variability, and a half-life of roughly 25 hours that allows once-daily dosing within an 8-hour window.
Option B: Option B describes insulin glargine, which precipitates at neutral pH rather than forming acylated multi-hexamers.
Option C: Option C describes insulin lispro, a rapid-acting analog whose B28-B29 reversal favors monomers and accelerates absorption.
Option D: Option D describes NPH (neutral protamine Hagedorn) insulin, an intermediate-acting protamine-zinc suspension.
Option E: Option E describes insulin glulisine, a rapid-acting analog whose substitutions destabilize self-association for fast onset, the opposite of degludec's ultra-long action.
9. A patient taking bedtime NPH (neutral protamine Hagedorn) insulin reports waking at about 3 in the morning with sweating and tremor that resolve after eating. Which property of NPH best explains these nocturnal episodes?
A) NPH has no peak effect, so any nocturnal symptoms must arise from a different cause
B) NPH is a rapid-acting analog that peaks within 1 to 2 hours of injection
C) NPH is an intermediate-acting insulin that peaks at roughly 4 to 8 hours after injection, so a bedtime dose peaks in the early morning hours and can precipitate nocturnal hypoglycemia
D) NPH precipitates at neutral subcutaneous pH to form a peakless 24-hour depot
E) NPH binds albumin reversibly through a fatty acid chain, buffering its action so it cannot cause hypoglycemia
ANSWER: C
Rationale:
NPH (neutral protamine Hagedorn) is an intermediate-acting insulin with onset of 1 to 2 hours, a pronounced peak at roughly 4 to 8 hours, and duration of 12 to 18 hours. A bedtime dose therefore peaks between about 2 and 4 in the morning, which is a recognized cause of nocturnal hypoglycemia; the patient's early-morning adrenergic symptoms fit this peak.
Option A: Option A is incorrect because NPH has a distinct peak, which is precisely the source of nocturnal hypoglycemia, unlike the peakless basal analogs.
Option B: Option B is incorrect because NPH is intermediate-acting, not a rapid-acting analog peaking at 1 to 2 hours.
Option D: Option D describes insulin glargine's pH-dependent peakless depot, not NPH.
Option E: Option E describes insulin detemir's albumin-binding mechanism, and the claim that it cannot cause hypoglycemia is false for any insulin.
10. Insulin detemir is distinctive among insulins for the very high degree to which it binds plasma protein. Which mechanism explains detemir's prolonged action and its approximately 98 percent plasma protein binding?
A) Precipitation into microprecipitates at neutral subcutaneous pH from an acidic vial solution
B) Formation of zinc-stabilized hexamers that must dissociate before absorption
C) Complexing with protamine to form an intermediate-acting suspension
D) A sequence reversal at B28-B29 that favors the monomer state and rapid absorption
E) Acylation of LysB29 with a C14 (fourteen-carbon) myristic acid chain, allowing reversible binding to albumin in the interstitium and bloodstream, which creates a prolonged-release depot and reduces the free fraction
ANSWER: E
Rationale:
Insulin detemir is produced by removing ThrB30 and acylating LysB29 with a C14 (fourteen-carbon) myristic acid chain. This fatty acid allows detemir to self-associate and to bind albumin reversibly in the subcutaneous interstitium and the bloodstream (about 98 percent albumin-bound), markedly lowering the free fraction and buffering absorption fluctuations to give a duration of 18 to 22 hours.
Option A: Option A describes insulin glargine's pH-dependent precipitation mechanism, not albumin binding.
Option B: Option B describes regular human insulin, whose zinc hexamers must dissociate before absorption and which is not highly albumin-bound.
Option C: Option C describes NPH (neutral protamine Hagedorn) insulin, a protamine suspension rather than an albumin-binding analog.
Option D: Option D describes a rapid-acting analog such as lispro, whose B28-B29 reversal accelerates absorption rather than prolonging it.
11. A patient using rapid-acting insulin at meals asks which injection site gives the fastest absorption to best blunt the post-meal glucose rise. Which anatomic site has the fastest subcutaneous insulin absorption?
A) The thigh, because its lower blood flow concentrates the depot
B) The abdomen, because greater subcutaneous blood flow there produces the fastest absorption and a sharper, earlier peak
C) The buttock, because its larger fat mass accelerates monomer release
D) The forearm, because it has the thinnest subcutaneous layer
E) All sites absorb at an identical rate, so site selection does not affect absorption
ANSWER: B
Rationale:
Subcutaneous insulin absorption is fastest from the abdomen because of its greater subcutaneous blood flow, intermediate from the arm, and slowest from the thigh and buttock. Abdominal injection of a rapid-acting insulin therefore produces a sharper, earlier peak that is well suited to mealtime bolus dosing.
Option A: Option A is incorrect because the thigh has slower, not faster, absorption, and lower blood flow delays rather than accelerates uptake.
Option C: Option C is incorrect because the buttock is among the slowest sites, and fat mass does not accelerate monomer release.
Option D: Option D is incorrect because the forearm is not the fastest site and is not a standard recommended injection region; abdominal blood flow, not skin thinness, governs the fastest absorption.
Option E: Option E is incorrect because absorption rate differs systematically by site, which is the basis for matching site to insulin type.
12. A lean patient using a longer needle has unpredictable episodes of hypoglycemia shortly after injecting insulin. Inadvertent intramuscular delivery is suspected. How does intramuscular injection alter insulin pharmacokinetics relative to correct subcutaneous placement?
A) It accelerates absorption, producing faster onset, a higher peak, and shorter duration, which is a recognized cause of unpredictable hypoglycemia
B) It slows absorption, delaying onset and lowering the peak concentration
C) It has no effect on absorption because muscle and subcutaneous tissue have identical blood flow
D) It prevents absorption entirely, so no clinical effect occurs
E) It converts the insulin into an inactive metabolite within the muscle before it can be absorbed
ANSWER: A
Rationale:
Intramuscular injection accelerates insulin absorption because of the higher blood flow of muscle, producing a faster onset, a higher peak, and a shorter duration than correct subcutaneous placement. This is a recognized cause of unpredictable hypoglycemia, particularly in lean patients using longer needles, which is why needle lengths of 4 to 6 mm are recommended to reliably achieve subcutaneous placement.
Option B: Option B is incorrect because intramuscular delivery speeds rather than slows absorption.
Option C: Option C is incorrect because muscle has greater blood flow than subcutaneous fat, so the two tissues do not behave identically.
Option D: Option D is incorrect because the insulin is still absorbed, indeed faster, rather than not at all.
Option E: Option E is incorrect because intramuscular insulin is not metabolized to an inactive form in muscle; it is absorbed more rapidly into the circulation.
13. A patient with longstanding diabetes who always injects into the same spot has unexplained, erratic glucose control, and palpation reveals a firm, rubbery thickening at the favored injection site. Which statement best explains the effect of this finding on insulin absorption?
A) Lipohypertrophy increases local vascularity, so insulin is absorbed faster and more predictably from these sites
B) Lipohypertrophy has no effect on absorption and is purely a cosmetic concern
C) Lipohypertrophy causes immediate destruction of injected insulin, so no insulin reaches the circulation
D) Lipohypertrophy creates poorly vascularized fibrofatty tissue that delays and makes erratic insulin absorption, a common cause of unexplained glycemic variability; switching to healthy tissue requires anticipatory dose reduction because absorption will increase
E) Lipohypertrophy accelerates absorption so reliably that injecting there is the preferred technique
ANSWER: D
Rationale:
Repeated injection at the same site causes lipohypertrophy, a fibrofatty enlargement with markedly reduced vascularization, and insulin injected into it has delayed, erratic absorption (onset may be delayed by 60 to 120 minutes), making it a common cause of unexplained glycemic variability. Because absorption increases sharply when injection moves to healthy tissue, rotation should be paired with temporary dose reduction.
Option A: Option A is incorrect because lipohypertrophic tissue is poorly vascularized, slowing and destabilizing absorption rather than speeding it.
Option B: Option B is incorrect because the absorption effect is clinically important, not merely cosmetic.
Option C: Option C is incorrect because insulin is still absorbed from these sites, just unpredictably, rather than destroyed.
Option E: Option E is incorrect because injecting into lipohypertrophic tissue worsens variability and is specifically discouraged, not preferred.
14. After insulin binds its receptor and is internalized, it is enzymatically degraded chiefly in the liver and kidney. Which enzyme is primarily responsible for insulin degradation?
A) Cytochrome P450 3A4 (CYP3A4), the major hepatic oxidative drug-metabolizing enzyme
B) Dipeptidyl peptidase-4 (DPP-4), which inactivates incretin hormones
C) Insulin-degrading enzyme (IDE), a zinc metalloprotease that cleaves insulin after receptor-mediated internalization and within endosomes
D) Acetylcholinesterase, which hydrolyzes its substrate at synaptic clefts
E) Plasma pseudocholinesterase (butyrylcholinesterase), the enzyme that hydrolyzes succinylcholine
ANSWER: C
Rationale:
Insulin is degraded primarily by insulin-degrading enzyme (IDE), a zinc metalloprotease that cleaves insulin after receptor-mediated internalization and within endosomes, acting mainly in the liver and kidney.
Option A: Option A is incorrect because insulin is a peptide cleared by proteolysis, not by CYP3A4 oxidative metabolism, which handles small-molecule drugs.
Option B: Option B is incorrect because DPP-4 inactivates incretins such as GLP-1 (glucagon-like peptide-1) and GIP, not insulin.
Option D: Option D is incorrect because acetylcholinesterase hydrolyzes acetylcholine at cholinergic synapses and has no role in insulin clearance.
Option E: Option E is incorrect because plasma pseudocholinesterase hydrolyzes esters such as succinylcholine and is unrelated to insulin degradation.
15. A patient with worsening chronic kidney disease and a falling eGFR (estimated glomerular filtration rate) begins having more frequent hypoglycemia on a previously stable insulin regimen. Which mechanism best explains the increased hypoglycemia risk?
A) Renal impairment increases insulin clearance, requiring higher insulin doses to maintain control
B) Renal impairment reduces insulin clearance because the kidney accounts for a substantial share of peripheral insulin degradation, so insulin action is prolonged and hypoglycemia risk rises, often requiring dose reduction
C) Renal impairment has no effect on insulin clearance because insulin is cleared exclusively by the liver
E) Renal impairment causes insulin resistance that uniformly raises insulin requirements without any hypoglycemia risk
ANSWER: B
Rationale:
The kidney accounts for roughly 30 to 40 percent of peripheral insulin degradation through glomerular filtration with tubular reabsorption and degradation, plus peritubular uptake. As renal function declines, insulin clearance falls, prolonging insulin action and predisposing to hypoglycemia, so dose reduction is generally required as eGFR (estimated glomerular filtration rate) falls below 30 mL/min/1.73m2.
Option A: Option A is incorrect because renal impairment reduces, not increases, insulin clearance, so requirements typically fall.
Option C: Option C is incorrect because the kidney, not the liver alone, handles a major share of peripheral insulin clearance.
Option D: Option D is incorrect because renal impairment does not induce IDE to accelerate insulin metabolism; clearance decreases.
Option E: Option E is incorrect because the dominant clinical effect described here is reduced clearance and hypoglycemia, not a uniform increase in requirements without hypoglycemia risk.
16. An insulin-naive adult with type 1 diabetes mellitus is starting a basal-bolus regimen. Which statement best reflects standard initial total daily dose (TDD) estimation and its basal-bolus division?
A) Start at about 2 units per kilogram per day, divided 90 percent basal and 10 percent bolus
B) Start at about 0.05 units per kilogram per day, given entirely as bolus insulin with no basal component
C) Start with basal insulin only at about 1 unit per kilogram per day, with no mealtime bolus
D) Start at about 0.4 to 0.5 units per kilogram per day, given entirely as a single bolus dose at the largest meal
E) Start at about 0.4 to 0.5 units per kilogram per day, divided roughly 50 percent basal and 50 percent bolus, with the bolus distributed across meals
ANSWER: E
Rationale:
For an insulin-naive patient with type 1 diabetes mellitus, the starting total daily dose (TDD) is typically estimated at 0.4 to 0.5 units per kilogram per day, divided approximately 50 percent basal and 50 percent bolus, with the bolus distributed across meals; the split is then adjusted based on fasting versus postprandial glucose patterns.
Option A: Option A is incorrect because 2 units per kilogram is far above a starting estimate and a 90/10 basal-bolus split does not provide adequate mealtime coverage in T1DM.
Option B: Option B is incorrect because an all-bolus regimen with no basal leaves hepatic glucose output unopposed between meals and overnight.
Option C: Option C is incorrect because T1DM, with absent endogenous secretion, requires both basal and bolus components, not basal alone.
Option D: Option D is incorrect because a single daily bolus does not match insulin delivery to the multiple daily postprandial excursions, and it omits the required basal component.
17. A patient on a basal-bolus regimen has a total daily dose (TDD) of 36 units. Using the 1800 Rule to estimate the correction factor (CF, also called insulin sensitivity factor), what is the approximate expected glucose-lowering effect of 1 unit of rapid-acting insulin?
A) Approximately 50 mg/dL per unit, because 1800 divided by the TDD of 36 equals 50, giving the estimated drop in glucose per unit
B) Approximately 15 mg/dL per unit, because the correction factor equals the carbohydrate-to-insulin ratio
C) Approximately 500 mg/dL per unit, because 500 divided by the TDD gives the correction factor
D) Approximately 36 mg/dL per unit, because the correction factor equals the total daily dose
E) Approximately 1800 mg/dL per unit, because the rule sets the correction factor equal to the constant 1800
ANSWER: A
Rationale:
The 1800 Rule estimates the correction factor (CF) as 1800 divided by the total daily dose (TDD): 1800 divided by 36 equals 50, so 1 unit of rapid-acting insulin is expected to lower glucose by approximately 50 mg/dL. This is a starting estimate requiring individual titration.
Option B: Option B is incorrect because it confuses the CF with the carbohydrate-to-insulin ratio (CIR), which is estimated by the 500 Rule (500 divided by TDD) and expresses grams of carbohydrate covered per unit, not mg/dL lowered.
Option C: Option C is incorrect because the 500 constant is used for the CIR, not the CF; using it here misapplies the rule and the arithmetic (500 divided by 36 is about 14, not a correction factor).
Option D: Option D is incorrect because the CF is not equal to the TDD; it is 1800 divided by the TDD.
Option E: Option E is incorrect because the rule divides 1800 by the TDD rather than setting the CF equal to 1800.
REFERENCE BOX
500 Rule: carbohydrate-to-insulin ratio (CIR, grams of carbohydrate per unit) is approximately 500 divided by the total daily dose (TDD).
1800 Rule: correction factor (CF, mg/dL lowered per unit of rapid-acting insulin) is approximately 1800 divided by the TDD.
Mealtime bolus = (grams of carbohydrate / CIR) + ((current glucose minus target glucose) / CF). These are starting estimates requiring individualized titration.
18. A patient using continuous subcutaneous insulin infusion (CSII, an insulin pump) has reproducible pre-breakfast hyperglycemia despite good control the rest of the day. The dawn phenomenon is suspected. Which statement correctly describes the dawn phenomenon and how CSII addresses it?
A) It is a late-night drop in glucose caused by the peak of bedtime NPH insulin, managed by reducing the basal rate at midnight
B) It is rebound hyperglycemia that always follows an episode of nocturnal hypoglycemia and is treated by lowering the total insulin dose
C) It is an early-morning rise in cortisol and growth hormone that increases hepatic glucose production and insulin resistance between roughly 3 and 8 in the morning, and CSII can counter it by programming an increased basal rate during that interval
D) It is caused by GLUT4 (glucose transporter type 4) overactivity in the early morning, corrected by a larger mealtime bolus at breakfast
E) It is an artifact of meter inaccuracy in the morning and requires no change in insulin delivery
ANSWER: C
Rationale:
The dawn phenomenon is the early-morning rise in cortisol and growth hormone that increases hepatic glucose production and insulin resistance between approximately 3 and 8 in the morning, producing pre-breakfast hyperglycemia. CSII (continuous subcutaneous insulin infusion) can be programmed to deliver an increased basal rate during this interval, an adjustment not achievable with a single once-daily basal analog injection.
Option A: Option A is incorrect because it describes nocturnal hypoglycemia from an NPH peak, which is a fall in glucose, not the early-morning hyperglycemia of the dawn phenomenon.
Option B: Option B describes the Somogyi concept of post-hypoglycemic rebound, which is distinct from the dawn phenomenon and not its defining mechanism.
Option D: Option D is incorrect because the dawn phenomenon results from counter-regulatory hormone-driven hepatic glucose output, not GLUT4 overactivity, and is better addressed by basal-rate programming than by enlarging a single bolus.
Option E: Option E is incorrect because the reproducible pattern reflects real physiology and does warrant a basal-rate adjustment, not dismissal as meter error.
19. An insulin-treated patient is scheduled for surgery and will be NPO (nil per os). Which approach reflects standard perioperative insulin management?
A) Hold all insulin, including basal, the night before and morning of surgery, and target a glucose of 80 to 110 mg/dL intraoperatively
B) Continue the full usual basal and bolus doses unchanged, targeting tight normoglycemia below 110 mg/dL
C) Give the full mealtime bolus insulin on schedule despite NPO status to prevent any hyperglycemia
D) Continue long-acting basal insulin at about 75 to 80 percent of the usual dose, hold rapid-acting bolus insulin while NPO, and target a glucose of 140 to 180 mg/dL
E) Switch the patient to subcutaneous NPH every 2 hours intraoperatively and target a glucose below 100 mg/dL
ANSWER: D
Rationale:
Standard perioperative management continues long-acting basal insulin at roughly 75 to 80 percent of the usual dose, holds all rapid-acting bolus insulin while the patient is NPO (nil per os), and targets a glucose of 140 to 180 mg/dL, balancing hyperglycemia risks against hypoglycemia, which is especially dangerous in an anesthetized patient who cannot report symptoms.
Option A: Option A is incorrect because withholding basal entirely risks hyperglycemia and ketosis in insulin-dependent patients, and an 80 to 110 mg/dL intraoperative target is too tight and raises hypoglycemia risk.
Option B: Option B is incorrect because giving full bolus doses to an NPO patient invites hypoglycemia, and a sub-110 target is not the perioperative goal.
Option C: Option C is incorrect because mealtime bolus insulin should be held, not given, when the patient is not eating.
Option E: Option E is incorrect because frequent subcutaneous NPH is not the standard perioperative method, and a sub-100 target is inappropriately tight; intravenous regular insulin infusion is used when prolonged precise control is needed.
20. Insulin-induced hypoglycemia produces symptoms in a characteristic sequence as glucose falls. Which statement correctly pairs the symptom category with its approximate glucose threshold and mechanism?
A) Neuroglycopenic symptoms such as sweating and tremor appear first at about 65 to 70 mg/dL, driven by direct neuronal glucose deprivation
B) Neurogenic (autonomic) symptoms such as sweating, tremor, palpitations, and hunger are triggered by the sympathoadrenal response at roughly 65 to 70 mg/dL, while neuroglycopenic symptoms such as confusion and visual disturbance appear at roughly 55 to 60 mg/dL from direct neuronal glucose deprivation
C) All hypoglycemia symptoms appear simultaneously only once glucose falls below 30 mg/dL
D) Neurogenic symptoms reflect direct neuronal glucose deprivation, whereas neuroglycopenic symptoms reflect the sympathoadrenal response
E) Hunger and palpitations are neuroglycopenic symptoms appearing below 40 mg/dL, while confusion is an autonomic symptom appearing at 70 mg/dL
ANSWER: B
Rationale:
Neurogenic (autonomic) symptoms such as sweating, tremor, palpitations, and hunger arise from the sympathoadrenal response triggered at a glucose threshold of approximately 65 to 70 mg/dL, providing early warning. Neuroglycopenic symptoms such as confusion, difficulty concentrating, behavioral change, and visual disturbance appear at approximately 55 to 60 mg/dL and reflect direct neuronal glucose deprivation, since the brain has essentially no glycogen reserve.
Option A: Option A is incorrect because sweating and tremor are neurogenic (autonomic), not neuroglycopenic, symptoms, and it mislabels the mechanism.
Option C: Option C is incorrect because symptoms emerge in a graded sequence as glucose falls through the 70 and then the 55 to 60 mg/dL range, not all at once below 30 mg/dL.
Option D: Option D is incorrect because it inverts the mechanisms: neurogenic symptoms reflect the sympathoadrenal response while neuroglycopenic symptoms reflect neuronal glucose deprivation.
Option E: Option E is incorrect because hunger and palpitations are neurogenic (autonomic) symptoms and confusion is neuroglycopenic, the reverse of what is stated.
21. A patient with longstanding type 1 diabetes mellitus reports that hypoglycemia now comes on without the usual warning symptoms; the first sign is often confusion. Recurrent hypoglycemia is suspected to have impaired the warning system. Which mechanism best explains this impaired awareness of hypoglycemia?
A) Recurrent hypoglycemia lowers the glucose threshold at which counter-regulatory responses and neurogenic symptoms are triggered, a phenomenon termed hypoglycemia-associated autonomic failure (HAAF), so neuroglycopenia can occur before adrenergic warning symptoms
B) The patient has developed insulin resistance, which abolishes hypoglycemia symptoms by raising the symptomatic threshold
C) Recurrent hypoglycemia raises the glucose threshold for counter-regulation, causing symptoms to appear earlier and more intensely than before
D) Impaired awareness reflects permanent destruction of pancreatic beta cells and is unrelated to prior hypoglycemic episodes
E) The symptoms are blunted because the brain has developed large glycogen reserves that buffer against glucose deprivation
ANSWER: A
Rationale:
Repeated hypoglycemic episodes reduce the glucose threshold at which counter-regulatory responses (epinephrine release, glucagon secretion) and neurogenic symptoms are triggered, a phenomenon termed hypoglycemia-associated autonomic failure (HAAF). The result is impaired awareness of hypoglycemia, in which neuroglycopenic impairment such as confusion can appear before the usual adrenergic warning; avoiding recurrent hypoglycemia for several weeks can partly restore awareness, and CGM (continuous glucose monitoring) with alerts is recommended.
Option B: Option B is incorrect because impaired awareness here is driven by recurrent hypoglycemia resetting the threshold, not by insulin resistance, which does not abolish hypoglycemia symptoms.
Option C: Option C is incorrect because recurrent hypoglycemia lowers rather than raises the counter-regulatory threshold, blunting rather than intensifying early symptoms.
Option D: Option D is incorrect because impaired awareness is functionally driven by prior hypoglycemia rather than being an unrelated consequence of beta-cell loss.
Option E: Option E is incorrect because the brain has essentially no glycogen reserve, so it cannot buffer against glucose deprivation in this way.
22. A patient with severe hypoglycemia who cannot take oral glucose is given intramuscular glucagon but responds poorly; the history is notable for prolonged fasting and heavy alcohol use. Which statement best explains glucagon's mechanism and the reason for the poor response?
A) Glucagon lowers glucose by stimulating peripheral glucose uptake, so it is ineffective when glucose is already low
B) Glucagon acts by promoting renal glucose reabsorption and fails when renal function is impaired
C) Glucagon raises glucose by directly inhibiting the insulin receptor, an effect overwhelmed by high circulating insulin
D) Glucagon raises glucose by stimulating intestinal glucose absorption, so it fails when the patient is NPO (nil per os)
E) Glucagon activates hepatic glucagon receptors (Gs-coupled, cAMP-mediated), activating glycogen phosphorylase to mobilize hepatic glycogen, so it is ineffective when glycogen is depleted, as in prolonged fasting or alcohol intoxication
ANSWER: E
Rationale:
Glucagon raises blood glucose by activating hepatic glucagon receptors, which are Gs-coupled and cAMP-mediated, thereby activating glycogen phosphorylase and mobilizing hepatic glycogen stores. Because it depends on available glycogen, glucagon is ineffective when hepatic glycogen is depleted, as in prolonged fasting, alcohol intoxication, or hepatic failure, which explains the poor response in this patient.
Option A: Option A is incorrect because glucagon raises glucose by mobilizing hepatic glycogen rather than stimulating peripheral glucose uptake.
Option B: Option B is incorrect because glucagon's glucose-raising action is hepatic glycogenolysis, not renal glucose reabsorption.
Option C: Option C is incorrect because glucagon acts through its own hepatic receptor and second-messenger cascade, not by directly inhibiting the insulin receptor.
Option D: Option D is incorrect because glucagon does not work by promoting intestinal glucose absorption; its effect is mobilization of hepatic glycogen, and NPO status is not the reason it fails here.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.